<DOC>
	<DOCNO>NCT01123655</DOCNO>
	<brief_summary>This Phase I clinical trial determine whether orally administer APL A12 one dose superior placebo effect 25 % reduction interferon ( IFN ) stimulation index 1 ( II ) -stimulated culture peripheral blood mononuclear ( PBMC ) obtain patient Rheumatoid Arthritis ( RA ) , primary outcome variable . In effort learn mechanism action APL A12 , investigator assess Th1/Th2/Th3 cytokine production supernatant 48h 144h culture PBMC stimulate 1 ( II ) APL A12 . The investigator assess function CD4+ CD25+ T regs determine whether APL A12 improve suppressive function . Flow cytometry combine intracellular cytokine stain use effort determine T cell subset ( ) is/are experience shift cytokine expression .</brief_summary>
	<brief_title>Phase 1 Trial Type II Collagen ( CII ) APL A12 Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>The study 3 treatment arm 10 patient demonstrate T cell immunity CII vitro response APL A12 screen visit . Patients randomize one 3 treatment arm . Each 3 treatment give 16 week . In keep sequential dose escalation strategy , originally propose randomization scheme modify subject randomize receive either low dose ( 30 mg ) placebo ( Block 1 ) , follow next dose ( 50 mg ) placebo ( Block 2 ) . We begin low dose ( 30 g/day ) enroll 6 receive 30 g/day APL A12 2 receive placebo 16 week . Results report Data Monitoring Committee ( DMC ) decision proceed next block base indication safety . If dose cause adverse event toxicity worsen RA , proceed enroll patient receive 30 ug , 50 g/day APL A12 placebo 16 week . A total 32 subject randomize obtain 24 subject complete study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients must meet follow criterion participation study . Male female ; age &gt; 18 year . American College Rheumatology ( ACR ) 1988 revise criterion rheumatoid arthritis . Onset disease age 16 older . Onset disease least 3 month prior enrollment . RA patient age 1885 RA 3 month duration opinion examine rheumatologist `` clinically stable '' likely require adjustment dos Diseasemodifying antirheumatic drug ( DMARDS ) , NSAIDS , prednisone , antitumor necrosis factor ( antiTNF ) alpha therapy 16 week treatment phase study . Patients must agree discontinue `` herbal remedy '' describe protocol . Women childbearing age advise use effective mean contraception treatment phase trial 90 day thereafter . They must negative urine pregnancy test randomization visit . ( Required FDA . ) Men advise use effective mean contraception treatment phase trial 90 day thereafter . ( Required FDA . ) Crohn 's Disease Activity Index ( CDAI ) less equal 30 baseline visit . Patients past history malignant neoplasm eligible 1 great year recurrence malignant neoplasm . Inability render inform consent accordance institutional guideline . Participation another clinical research study involve evaluation another investigational drug within 90 day entry study . RA patient &gt; 7.5 mg prednisone day . RA patient intraarticular corticosteroid injection previous 30 day . Concurrent serious medical condition opinion investigator make patient inappropriate study . Hepatitis B abd/or C patient inactive disease ( determined PI ) enrol . Positive urine pregnancy test Age 85 year great . Use `` fish oil '' within previous 4 week baseline visit . Therapy consist auranofin cyclophosphamide ( DMARDs allow ) . Previous autologous heterologous stem cell transplantation . Active malignant neoplasm past treatment malignant neoplasm 1 year screen visit . Use oral CII within past 1 year . ( Since oral tolerance shortlived , permit patient study oral CII &gt; 1 year ) Diabetes require insulin oral medication must well manage baseline . Adjustment insulin oral medication allow study . Serum creatinine 2.0 mcg/dL . An 1 ( II ) IFN value &lt; 100 % PBS IFN value within 1 month less prior baseline le 25 % reduction APL A12 + 1 ( II ) IFN 1 ( II ) IFN concentration . CDAI &gt; 30 baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>